Revance Begins Injectable Trial

Revance Therapeutics, a biopharmaceutical company, has announced Phase 2 BELMONT trial. This randomized, double-blind, dose ranging, active, and placebo controlled, multicenter study will evaluate the safety and efficacy of RT002, a botulinum toxin type A injectable intended to treat glabellar lines. The RT002 has the potential to address additional therapeutic indications where more targeted delivery is required or a longer duration is desired, for example movement disorders, urology, and ophthalmology. There are 250 participants expected to enroll at up to 10 sites in Canada. “The opportunity for a longer-lasting, more targeted neurotoxin is tremendous as it offers the potential for improved patient satisfaction and safety with longer-lasting results,” says Dan Browne, cofounder, president, and CEO of Revance Therapeutics. “Based on the current progress of our program, we expect to report top-line date from this Phase 2 study in late 2015.”

Suggested Articles

The 2020 donations support programs dedicated to the COVID-19 pandemic response, as well as initiatives supporting mental health, eye care, and breast

The scholarship, hosted by Beauty Changes Lives, is for licensed business owners of salons and spas who seek to make the industry more sustainable.

Many businesses are thinking out the box when it comes to serving their clients, and that's true for some in the medical aesthetics field.